Oral pentobarbital suspension for children sedation during MR imaging

Area of Science:

• Pediatric Radiology
• Pharmacology

Background:

• Pediatric Magnetic Resonance (MR) imaging often requires sedation for successful completion.
• Oral pentobarbital suspension is a potential agent for pediatric sedation, but its efficacy and safety require evaluation.

Purpose of the Study:

• To assess the efficacy and safety of oral pentobarbital suspension for sedation in children undergoing MR imaging.
• To determine the optimal dosage and evaluate factors influencing sedation success.

Main Methods:

• A prospective study involving 81 children (8 months to 8 years) receiving oral pentobarbital suspension (5mg/kg).
• Key parameters recorded included sedation time, duration, discharge time, imaging quality, and adverse events.
• Success rates were analyzed based on age groups.

Main Results:

• Oral pentobarbital suspension achieved a 100% sedation success rate in infants under 12 months, with no adverse effects.
• Overall imaging quality was satisfactory in 67% of patients.
• Sedation success rates decreased with age: 76% for 1-3 years and 42% for 4-8 years, with drug taste cited as a failure reason.

Conclusions:

• Oral pentobarbital suspension is highly effective and safe for sedating infants under 12 months for MR imaging.
• The efficacy of oral pentobarbital suspension decreases in older children, potentially due to palatability issues.
• Further research may explore strategies to improve taste and efficacy in older pediatric populations.